Egerton Capital (UK) LLP John Armitage
London, X0 24 processed 13Fs on this site, 2021 Q3 to 2026 Q3
- $9.8B
- 23 holdings
- 2026 Q3
- −5.1% QoQ
- Top 5 52.3%
AUM over time
Book
| Canadian Pacific Railway | Reduce −13.5% | 17,587,143 | $76.94 | $1.4B | −2,746,040 | −$163M | |
| CNI, Canadian National Railway | Reduce −20.7% | 8,710,030 | $117.97 | $1B | −2,271,953 | −$278M | |
| V, Visa | Add +10.6% | 4,184,668 | $225.46 | $943M | +401,354 | +$157M | |
| FCNCA, First Citizens Bancshares | Reduce −15.1% | 603,018 | $973.10 | $587M | −107,364 | +$48M | |
| SLB | Reduce −10.1% | 9,905,496 | $49.10 | $486M | −1,108,139 | −$102M | |
| CVE, Cenovus Energy | Reduce −12.5% | 25,134,420 | $17.46 | $439M | −3,593,767 | −$119M | |
| FISV, Fiserv | New | 3,499,199 | $113.03 | $396M | +3,499,199 | +$396M | |
| MSFT, Microsoft | Reduce −45.3% | 1,327,478 | $288.30 | $383M | −1,099,578 | −$199M | |
| META, Meta Platforms | New | 1,755,537 | $211.94 | $372M | +1,755,537 | +$372M | |
| MA, Mastercard | Reduce −50.1% | 999,181 | $363.41 | $363M | −1,002,025 | −$333M | |
| TECK, Teck Resources | Reduce −12.8% | 9,936,175 | $36.50 | $363M | −1,459,884 | −$68M | |
| ADI, Analog Devices | Reduce −8.7% | 1,796,504 | $197.22 | $354M | −172,153 | +$31M | |
| AMAT, Applied Materials | Add +10.2% | 2,722,141 | $122.83 | $334M | +252,285 | +$94M | |
| GOOG, Alphabet | Reduce −65.0% | 2,892,080 | $104.00 | $301M | −5,360,863 | −$432M | |
| LOW, Lowe's | Reduce −50.9% | 1,119,576 | $199.97 | $224M | −1,159,249 | −$230M | |
| LPLA, LPL Financial | Reduce −17.0% | 1,019,727 | $202.40 | $206M | −208,517 | −$59M | |
| KKR | Reduce −12.6% | 3,851,728 | $52.52 | $202M | −556,114 | −$2.3M | |
| BKNG, Booking Holdings | Reduce −66.5% | 72,543 | $2,652 | $192M | −144,275 | −$245M | |
| IBN, Icici Bank | Reduce −25.2% | 7,644,873 | $21.58 | $165M | −2,570,107 | −$59M | |
| HDB, HDFC Bank | New | 2,347,386 | $66.67 | $157M | +2,347,386 | +$157M | |
| EG, Everest Group | Reduce −9.5% | 406,646 | $358.02 | $146M | −42,655 | −$3.3M | |
| RNR, RenaissanceRe | New | 623,152 | $200.34 | $125M | +623,152 | +$125M | |
| TMO, Thermo Fisher Scientific | New | 106,751 | $576.37 | $62M | +106,751 | +$62M | |
| LIN, Linde | New | 119,255 | $355.44 | $42M | +119,255 | +$42M | |
| UNH, UnitedHealth Group | Reduce −91.6% | 89,364 | $472.59 | $42M | −974,662 | −$522M |
Exits / last held
Gone since 2022 Q4, shown at their last reported size.
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| SCHW, Charles Schwab | Exit | 0 | $83.26 | $791M | −9,498,276 | −$791M | |
| CSX | Exit | 0 | $30.98 | $235M | −7,574,429 | −$235M |
Filings history
21 periods, with AUM normalized
| Period | Holds | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q3 | 23 | $9.8B | −5.1% | 13F-HR | 10/20/2026 | 000158181126000009 |
| 2026 Q2 | 23 | $10.4B | +14.9% | 13F-HR | 7/21/2026 | 000158181126000007 |
| 2026 Q1 | 24 | $9B | −2.1% | 13F-HR | 5/13/2026 | 000158181126000005 |
| 2025 Q4 | 23 | $9.2B | −3.0% | 13F-HR | 2/11/2026 | 000158181126000002 |
| 2025 Q3 | 24 | $9.5B | −2.7% | 13F-HR | 11/12/2025 | 000158181125000010 |
| 2025 Q2 | 25 | $9.7B | +12.5% | 13F-HR | 8/12/2025 | 000158181125000007 |
| 2025 Q1 | 27 | $8.7B | +0.2% | 13F-HR | 5/6/2025 | 000158181125000005 |
| 2024 Q4 | 30 | $8.6B | −12.7% | 13F-HR | 2/10/2025 | 000158181125000004 |
| 2024 Q3 | 30 | $9.9B | +0.1% | 13F-HR | 11/5/2024 | 000158181124000009 |
| 2024 Q2 | 26 | $9.9B | −4.3% | 13F-HR | 8/13/2024 | 000158181124000007 |
| 2024 Q1 | 22 | $10.3B | +12.1% | 13F-HR | 5/13/2024 | 000158181124000004 |
| 2023 Q4 | 22 | $9.2B | +7.1% | 13F-HR | 2/12/2024 | 000158181124000003 |
| 2023 Q3 | 22 | $8.6B | −11.2% | 13F-HR | 11/13/2023 | 000158181123000006 |
| 2023 Q2 | 23 | $9.7B | +4.7% | 13F-HR | 8/10/2023 | 000158181123000005 |
| 2023 Q1 | 25 | $9.3B | −20.3% | 13F-HR | 5/9/2023 | 000158181123000004 |
| 2022 Q4 | 21 | $11.6B | −9.8% | 13F-HR | 2/7/2023 | 000158181123000002 |
| 2022 Q3 | 23 | $12.9B | −13.1% | 13F-HR | 11/10/2022 | 000158181122000008 |
| 2022 Q2 | 26 | $14.8B | −21.9% | 13F-HR | 8/9/2022 | 000158181122000007 |
| 2022 Q1 | 29 | $19B | — | RESTATEMENT | 8/3/2022 | 000091957422004541 |
| 2022 Q1 | 29 | $19B | −11.5% | 13F-HR | 5/9/2022 | 000158181122000004 |
| 2021 Q4 | 32 | $21.4B | — | RESTATEMENT | 8/3/2022 | 000091957422004539 |
| 2021 Q4 | 32 | $21.4B | +1.9% | 13F-HR | 2/11/2022 | 000158181122000003 |
| 2021 Q3 | 34 | $21B | — | RESTATEMENT | 8/3/2022 | 000091957422004537 |
| 2021 Q3 | 34 | $21B | — | 13F-HR | 11/8/2021 | 000158181121000007 |
About
Egerton Capital (UK) LLP
24 processed 13Fs on this site, 2021 Q3 to 2026 Q3